title: Bactericidal permeability increasing protein gene polymorphism is associated with inflammatory bowel diseases in the Turkish population.
abstract: OBJECTIVE
  Inflammatory bowel disease, a chronic inflammatory disease with unknown etiology, affects the small and large bowel at different levels. It is increasingly considered that innate immune system may have a central position in the pathogenesis of the disease. As a part of the innate immune system, bactericidal permeability increasing protein has an important role in the recognition and neutralization of gram-negative bacteria. The aim of our study was to investigate the involvement of bactericidal permeability increasing protein gene polymorphism (bactericidal permeability increasing protein Lys216Glu) in inflammatory bowel disease in a large group of Turkish patients.
  
  
  METHODS
  The present study included 528 inflammatory bowel disease patients, 224 with Crohn's disease and 304 with ulcerative colitis, and 339 healthy controls.
  
  
  RESULTS
  Bactericidal permeability increasing protein Lys216Glu polymorphism was found to be associated with both Crohn's disease and ulcerative colitis (P = 0.0001). The frequency of the Glu/Glu genotype was significantly lower in patients using steroids and in those with steroid dependence (P = 0.012, OR, 0.80; 95% confidence interval [CI]: 0.68-0.94; P = 0.0286, OR, 0.75; 95% CI: 0.66-0.86, respectively). There was no other association between bactericidal permeability increasing protein gene polymorphism and phenotypes of inflammatory bowel disease.
  
  
  CONCLUSIONS
  Bactericidal permeability increasing protein Lys216Glu polymorphism is associated with both Crohn's disease and ulcerative colitis. This is the first study reporting the association of bactericidal permeability increasing protein gene polymorphism with steroid use and dependence in Crohn's disease.
authors.affiliation: Department of Gastroenterology, Abant İzzet Baysal University, Faculty of Medicine, Bolu, Turkey.
authors.forename: Güray
authors.initials: G
authors.lastname: Can
authors.forename: Hakan
authors.initials: H
authors.lastname: Akın
authors.forename: Filiz T
authors.initials: FT
authors.lastname: Özdemir
authors.forename: Hatice
authors.initials: H
authors.lastname: Can
authors.forename: Bülent
authors.initials: B
authors.lastname: Yılmaz
authors.forename: Fatih
authors.initials: F
authors.lastname: Eren
authors.forename: Özlen
authors.initials: Ö
authors.lastname: Atuğ
authors.forename: Belkıs
authors.initials: B
authors.lastname: Ünsal
authors.forename: Hülya O
authors.initials: HO
authors.lastname: Hamzaoğlu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D023181:Antimicrobial Cationic Peptides / Q000235:genetics*; D001798:Blood Proteins / Q000235:genetics*; D016022:Case-Control Studies; D003093:Colitis, Ulcerative / Q000235:genetics*; D003424:Crohn Disease / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics*; D014421:Turkey; D055815:Young Adult
chemical_list: D023181:Antimicrobial Cationic Peptides; D001798:Blood Proteins; C021623:bactericidal permeability increasing protein